Is PHASQ or NOBL a better dividend investment in 2026?

PHASQ currently yields 200000000.00% with a 5% 5-year dividend growth rate. NOBL yields 2.17% with 5% growth. The better choice depends on your goal: PHASQ offers higher current income.

What is the dividend yield difference between PHASQ and NOBL?

PHASQ has a forward dividend yield of 200000000.00% ($2.00/share annually). NOBL yields 2.17% ($2.27/share annually). The yield gap is 199999997.83 percentage points.

Home › Compare › PHASQ vs NOBL

PHASQ vs NOBL: Dividend Comparison 2026

PHASQ yields 200000000.00% · NOBL yields 2.17%● Live data

vsPost on X →

After 10 years · $10,000 invested · DRIP enabled

🏆 PHASQ wins by $4.875657285131069e+59M in total portfolio value

INVESTMENT

TIME HORIZON10 years

PHASQ

● Live price

200000000.00%

Share price

$0.00

Annual div

$2.00

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$4.875657285131069e+59M

Annual income

$487,565,248,955,786,300,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000.00

Full PHASQ calculator →

NOBL

● Live price

2.17%

Share price

$104.67

Annual div

$2.27

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$22.9K

Annual income

$249.78

Full NOBL calculator →

Portfolio growth — PHASQ vs NOBL

📍 PHASQ pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis Period	PHASQ	NOBL
2008–2009 GFC	— No data	— No data
2020 Q1–Q2 COVID	— No data	— No data
2022 Q4 Rate Hike	— No data	— No data

Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.

📅

Dividend Calendar Overlap

Combined, PHASQ + NOBL cover 0 of 12 months — good coverage

Jan

—

Feb

—

Mar

—

Apr

—

May

—

Jun

—

Jul

—

Aug

—

Sep

—

Oct

—

Nov

—

Dec

—

PHASQ pays

NOBL pays

Both pay

Neither

💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

PHASQ

Annual income on $10K today (after 15% tax)

$17,000,000,000.00/yr

After 10yr DRIP, annual income (after tax)

$414,430,461,612,418,300,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000.00/yr

NOBL

Annual income on $10K today (after 15% tax)

$184.52/yr

After 10yr DRIP, annual income (after tax)

$212.31/yr

At 15% tax rate, PHASQ beats the other by $414,430,461,612,418,300,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000

⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of PHASQ + NOBL for your $10,000?

PHASQ: 50%NOBL: 50%

100% NOBL50/50100% PHASQ

Portfolio after 10yr

$2.4378286425655345e+59M

Annual income

$243,782,624,477,893,130,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000.00/yr

Blended yield

100.00%

🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

PHASQ buys

NOBL buys

No recent congressional trades found for PHASQ or NOBL in the last 90 days.

STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →

MetricPHASQNOBL

Forward yield	200000000.00% ✓	2.17%
Annual dividend / share	$2.00	$2.27 ✓
Payout ratio	50%	50%
1-year div growth	0%	0%
5-year div CAGR	0%	0%
Portfolio after 10y	$4.875657285131069e+59M	$22.9K ✓
Annual income after 10y	$487,565,248,955,786,300,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000.00 ✓	$249.78
Total dividends collected	$4.875656971401711e+59M ✓	$2.3K
Payment frequency	quarterly	quarterly
Sector	Stock	ETF

Year-by-year: PHASQ vs NOBL ($10,000, DRIP)

Year	PHASQ Portfolio	PHASQ Income/yr	NOBL Portfolio	NOBL Income/yr	Gap
1← crossover	$20,000,010,700	$20,000,000,000.00	$10,917	$217.08	+$20000.00M → PHASQ
2	$37,383,218,970,104,910	$37,383,197,570,093,464.00	$11,903	$221.48	+$37383218970.09M → PHASQ
3	$65,303,942,472,059,150,000,000	$65,303,902,472,014,860,000,000.00	$12,962	$225.68	+$65303942472059152.00M → PHASQ
4	$106,615,009,060,306,890,000,000,000,000	$106,614,939,185,088,440,000,000,000,000.00	$14,099	$229.68	+$1.0661500906030689e+23M → PHASQ
5	$162,672,273,967,082,950,000,000,000,000,000,000	$162,672,159,889,023,270,000,000,000,000,000,000.00	$15,319	$233.49	+$1.6267227396708296e+29M → PHASQ
6	$231,966,340,306,755,300,000,000,000,000,000,000,000,000	$231,966,166,247,422,140,000,000,000,000,000,000,000,000.00	$16,628	$237.10	+$2.319663403067553e+35M → PHASQ
7	$309,138,182,305,146,600,000,000,000,000,000,000,000,000,000,000	$309,137,934,101,162,400,000,000,000,000,000,000,000,000,000,000.00	$18,033	$240.53	+$3.091381823051466e+41M → PHASQ
8	$385,031,777,252,258,400,000,000,000,000,000,000,000,000,000,000,000,000	$385,031,446,474,403,340,000,000,000,000,000,000,000,000,000,000,000,000.00	$19,539	$243.78	+$3.850317772522584e+47M → PHASQ
9	$448,184,411,799,345,900,000,000,000,000,000,000,000,000,000,000,000,000,000,000	$448,183,999,815,344,300,000,000,000,000,000,000,000,000,000,000,000,000,000,000.00	$21,154	$246.86	+$4.481844117993459e+53M → PHASQ
10	$487,565,728,513,106,900,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000	$487,565,248,955,786,300,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000.00	$22,884	$249.78	+$4.875657285131069e+59M → PHASQ

PHASQ vs NOBL: Complete Analysis 2026

PHASQ — Stock

PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel for cardiovascular diseases. Its lead product candidate is bentracimab (PB2452), a reversal agent for the antiplatelet drug ticagrelor that is in Phase III clinical trial for patients with uncontrolled major or life-threatening bleeding events or in patients requiring urgent or an invasive procedure. The company is also developing PB1046, a vasoactive intestinal peptide analogue for the treatment of pulmonary arterial hypertension; and PB6440 for the treatment of resistant hypertension. The company has a co-development agreement with SFJ Pharmaceuticals X, Ltd. to develop PB2452, a reversal agent for the antiplatelet drug ticagrelor. PhaseBio Pharmaceuticals, Inc. was incorporated in 2002 and is based in Malvern, Pennsylvania. On October 23, 2022, PhaseBio Pharmaceuticals, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.

Full PHASQ Calculator →

NOBL — ETF

The fund will invest at least 80% of its total assets in component securities of the index. The index contains a minimum of 40 stocks, which are equally weighted, and no single sector is allowed to comprise more than 30% of the index weight. It seeks to remain fully invested at all times in securities and/or financial instruments that, in combination, provide exposure to the returns of the index without regard to market conditions, trends or direction.

Full NOBL Calculator →

📬

Get this PHASQ vs NOBL comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

PHASQ vs SCHD PHASQ vs JEPI PHASQ vs O PHASQ vs KO PHASQ vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.